scholarly journals Prevalence of resistant hypertension in uncontrolled hypertensive patients seen in consultation

2022 ◽  
Vol 14 (1) ◽  
pp. 96
Author(s):  
A. Taleb ◽  
A. Bachir Cherif ◽  
N. Damene Debbih ◽  
M.T. Bouafia
Keyword(s):  
Resistant Hypertension ◽  
Hypertensive Patients

Should all Hypertensive Patients be Screened for Primary Aldosteronism?

2019 ◽  
Vol 15 (1) ◽  
pp. 54-56
Author(s):  
Stelina Alkagiet ◽  
Konstantinos Tziomalos
Keyword(s):  
Resistant Hypertension ◽  
Primary Aldosteronism ◽  
Large Scale ◽  
Controlled Trial ◽  
The Other ◽  
Limited Data ◽  
Hypertensive Patients ◽  
Randomized Controlled ◽  
Increased Risk ◽  
Prospective Randomized Controlled Trial

Primary aldosteronism (PA) is not only a leading cause of secondary and resistant hypertension, but is also quite frequent in unselected hypertensive patients. Moreover, PA is associated with increased cardiovascular risk, which is disproportionate to BP levels. In addition, timely diagnosis of PA and prompt initiation of treatment attenuate this increased risk. On the other hand, there are limited data regarding the usefulness of screening for PA in all asymptomatic or normokalemic hypertensive patients. More importantly, until now, no well-organized, large-scale, prospective, randomized controlled trial has proved the effectiveness of screening for PA for improving clinical outcome. Accordingly, until more relevant data are available, screening for PA should be considered in hypertensive patients with spontaneous or diuretic-induced hypokalemia as well as in those with resistant hypertension. However, screening for PA in all hypertensive patients cannot be currently recommended.

scholarly journals Incidence and persistence of resistant hypertension among treated hypertensive patients: insights from a 4-year follow-up study

2013 ◽  
Vol 34 (suppl 1) ◽  
pp. 3613-3613
Author(s):  
A. Kordalis ◽  
C. Tsioufis ◽  
A. Kasiakogias ◽  
C. Thomopoulos ◽  
I. Dima ◽  
...  
Keyword(s):  
Resistant Hypertension ◽  
Hypertensive Patients ◽  
Follow Up Study

scholarly journals Burden of Resistant Hypertension in Hypertensive Patients with Non-Dialysis Chronic Kidney Disease

2011 ◽  
Vol 34 (1) ◽  
pp. 58-67 ◽  
Author(s):  
Luca De Nicola ◽  
Silvio Borrelli ◽  
Francis B. Gabbai ◽  
Paolo Chiodini ◽  
Pasquale Zamboli ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Resistant Hypertension ◽  
Hypertensive Patients

scholarly journals Prevalence and risk factors for resistant hypertension among hypertensive patients from a developing country

2013 ◽  
Vol 6 (1) ◽  
pp. 373 ◽  
Author(s):  
WA Nuwan Kumara ◽  
Thisara Perera ◽  
Mekhala Dissanayake ◽  
Priyanga Ranasinghe ◽  
Godwin R Constantine
Keyword(s):  
Risk Factors ◽  
Developing Country ◽  
Resistant Hypertension ◽  
Hypertensive Patients

scholarly journals Factors associated with resistant hypertension in a large cohort of hypertensive patients: the Pol-Fokus study

2015 ◽  
Vol 125 (4) ◽  
pp. 249-259
Author(s):  
Aleksander Prejbisz ◽  
Marek Klocek ◽  
Jerzy Gąsowski ◽  
Roman Topór-Mądry ◽  
Wiktoria Leśniak ◽  
...  
Keyword(s):  
Resistant Hypertension ◽  
Large Cohort ◽  
Hypertensive Patients ◽  
Factors Associated

scholarly journals Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing

Hypertension ◽  
2021 ◽  
Author(s):  
Dan Lane ◽  
Alexander Lawson ◽  
Angela Burns ◽  
Michel Azizi ◽  
Michel Burnier ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Resistant Hypertension ◽  
Antihypertensive Medication ◽  
Antihypertensive Drugs ◽  
Test Results ◽  
Sample Collection ◽  
Treatment Resistant ◽  
Blood Samples ◽  
Hypertensive Patients ◽  
Adherence Test

Nonadherence to antihypertensive medication is common, especially in those with apparent treatment-resistant hypertension (true treatment-resistant hypertension requires exclusion of nonadherence), and its routine detection is supported by clinical guidelines. Chemical adherence testing is a reliable and valid method to detect adherence, yet methods are unstandardized and are not ubiquitous. This article describes the principles of chemical adherence testing for hypertensive patients and provides a set of recommendations for centers wishing to develop the test. We recommend testing should be done in either of two instances: (1) in those who have resistant hypertension or (2) in those on 2 antihypertensives who have a less than 10 mm Hg drop in systolic blood pressure on addition of the second antihypertensive medication. Furthermore, we recommend that verbal consent is secured before undertaking the test, and the results should be discussed with the patient. Based on medications prescribed in United Kingdom, European Union, and United States, we list top 20 to 24 drugs that cover >95% of hypertension prescriptions which may be included in the testing panel. Information required to identify these medications on mass spectrometry platforms is likewise provided. We discuss issues related to ethics, sample collection, transport, stability, urine versus blood samples, qualitative versus quantitative testing, pharmacokinetics, instrumentation, validation, quality assurance, and gaps in knowledge. We consider how to best present, interpret, and discuss chemical adherence test results with the patient. In summary, this guidance should help clinicians and their laboratories in the development of chemical adherence testing of prescribed antihypertensive drugs.

scholarly journals The prevalence and associated cardiovascular risk factors in resistant hypertensive subjects in Eastern India

2014 ◽  
Vol 5 (4) ◽  
pp. 1-5 ◽  
Author(s):  
Pijush Kanti Mandal ◽  
Arpan Kumar Day ◽  
Subhraprakash Pramanik ◽  
Shovan Kumar Das ◽  
Sumit Khotick ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Heart Disease ◽  
Cardiovascular Risk ◽  
Ischemic Heart Disease ◽  
Cardiovascular Risk Factors ◽  
Resistant Hypertension ◽  
P Value ◽  
Hypertensive Patients ◽  
Co Morbidity

Background: To study the prevalence and associated cardiovascular risk factors of ‘Resistant’ hypertension (RHT) in hypertensive patients of India.Methods: A descriptive cross-sectional observational study was carried out among 300 hypertensive patients attending ‘Hypertension Clinic’ and providing informed written consent from October 2013 to December 2013 at Burdwan Medical College and hospital, Burdwan, West Bengal in India. A pre-tested interviewer-administered questionnaire was used for data collection. Results: The prevalence of Resistant hypertension was 23.33% among all hypertensives. The patients with Resistant hypertension were significantly associated with older age groups (>55 years) (77.1% vs. 38.3%, p value <0.001, OR 5.446, 95% CI 2.935 and 10.104), Obesity (BMI > 27.5 kg/m2) (67.1% vs. 45.7%, p value 0.002, OR 2.433, 95% CI 1.387 and 4.268), Diabetes mellitus (72.9% vs. 45.2%, p value <0.001, OR 3.252, 95% CI 1.808 and 5.851), Prolonged hypertension (>10 years; 74.3% vs. 43.9%, p value <0.001, OR 3.690, 95% CI 2.033 and 6.696) and co-morbidity like Ischemic Heart Disease (60% vs. 44.8%, p value 0.026, OR 1.850, 95% CI 1.073 and 3.187) as risk factors as compared to patients with non-resistant hypertension. Conclusions: Nearly one fourth of the hypertensive persons were suffering from Resistant hypertension, which was significantly associated with the presence of older age, obesity, diabetes mellitus, longer duration of hypertension and co-morbidity like Ischemic Heart Disease as risk factors. DOI: http://dx.doi.org/10.3126/ajms.v5i4.9737 Asian Journal of Medical Sciences 2014 Vol.5(4); 1-5

Novel device therapies for resistant hypertension

2018 ◽  
pp. 717-730
Author(s):  
Kenneth Chan ◽  
Manish Saxena ◽  
Melvin D. Lobo
Keyword(s):  
Blood Pressure ◽  
Resistant Hypertension ◽  
Antihypertensive Agents ◽  
Cardiovascular Morbidity ◽  
Office Blood Pressure ◽  
Morbidity And Mortality ◽  
Hypertensive Patients ◽  
Novel Device ◽  
Cardiovascular Morbidity And Mortality ◽  
Increased Risk

Resistant hypertension (RHTN) is defined as uncontrolled office blood pressure (>140/90 mmHg) despite treatment with maximum tolerated doses of three or more antihypertensive agents from at least three different classes, including a diuretic. The prevalence of RHTN is about 8–18% in hypertensive patients and confers greatly increased risk of cardiovascular morbidity and mortality.

Sign in / Sign up

Export Citation Format

Share Document